Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,150 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03476928 | A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding(ASTEROID 8) | terminated | Phase 3 | 153 | BayerINDUSTRY | 1 | Jul 8, 2022 | clinicaltrials |
| NCT02569242 | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer | completed | Phase 3 | 419 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 8 | Jul 6, 2022 | clinicaltrials |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | terminated | Phase 3 | 103 | BayerINDUSTRY | 5 | Jun 30, 2022 | clinicaltrials |
| NCT02200614 | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer(ARAMIS) | completed | Phase 3 | 1,509 | BayerINDUSTRY | 36 | Jun 28, 2022 | clinicaltrials |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | completed | Phase 3 | 499 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 17 | Jun 9, 2022 | clinicaltrials |
| NCT01239797 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma(ELOQUENT - 2) | completed | Phase 3 | 646 | Bristol-Myers SquibbINDUSTRY | 23 | Jun 1, 2022 | clinicaltrials |
| NCT04461886 | A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I | terminated | Phase 3 | 100 | NobelpharmaINDUSTRY | 1 | May 24, 2022 | clinicaltrials |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) | terminated | Phase 3 | 130 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01207011 | Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer | completed | Phase 3 | 202 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02810457 | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer(AVANA) | completed | Phase 3 | 731 | Centus Biotherapeutics LimitedINDUSTRY | 24 | Mar 10, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT02247232 | Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer | completed | Phase 3 | 793 | Zeria PharmaceuticalINDUSTRY | 7 | Mar 4, 2022 | clinicaltrials |
| NCT03669588 | An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness(ADAPT) | completed | Phase 3 | 167 | argenxINDUSTRY | 16 | Feb 8, 2022 | clinicaltrials |
| NCT04034355 | Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer(POLAR-A) | terminated | Phase 3 | 301 | Egetis TherapeuticsINDUSTRY | 10 | Jan 26, 2022 | clinicaltrials |
| NCT03085095 | A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer(HERO) | completed | Phase 3 | 1,134 | Myovant Sciences GmbHINDUSTRY | 22 | Jan 18, 2022 | clinicaltrials |
| NCT02773524 | A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer(INTEGRATEIIa) | unknown | Phase 3 | 250 | Australasian Gastro-Intestinal Trials GroupNETWORK | 7 | Jan 13, 2022 | clinicaltrials |
| NCT02322593 | Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer(SOLAR) | completed | Phase 3 | 711 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 2 | Dec 20, 2021 | clinicaltrials |
| NCT03654729 | Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)(POLAR-M) | terminated | Phase 3 | 291 | Egetis TherapeuticsINDUSTRY | 13 | Dec 17, 2021 | clinicaltrials |
| NCT00063999 | Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | completed | Phase 3 | 1,381 | GOG FoundationNETWORK | 3 | Oct 19, 2021 | clinicaltrials |
| NCT02551159 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer(KESTREL) | completed | Phase 3 | 823 | AstraZenecaINDUSTRY | 23 | Oct 13, 2021 | clinicaltrials |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | terminated | Phase 3 | 4,509 | AmgenINDUSTRY | 39 | Sep 28, 2021 | clinicaltrials |
| NCT02366143 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(IMpower150) | completed | Phase 3 | 1,202 | Hoffmann-La RocheINDUSTRY | 26 | Sep 23, 2021 | clinicaltrials |
| NCT02314117 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer(RAINFALL) | completed | Phase 3 | 645 | Eli Lilly and CompanyINDUSTRY | 20 | Aug 26, 2021 | clinicaltrials |
| NCT03349710 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | completed | Phase 3 | 74 | Bristol-Myers SquibbINDUSTRY | 10 | Aug 9, 2021 | clinicaltrials |
| NCT01524783 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)(RADIANT-4) | completed | Phase 3 | 302 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 5, 2021 | clinicaltrials |
| NCT03093870 | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer(TreeTopp) | completed | Phase 2 / Phase 3 | 151 | ASLAN PharmaceuticalsOTHER | 11 | Aug 3, 2021 | clinicaltrials |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)(MERU) | terminated | Phase 3 | 748 | AbbVieINDUSTRY | 41 | Jul 29, 2021 | clinicaltrials |
| NCT03123939 | Phase III B in Acute Lymphoblastic Leukemia | completed | Phase 3 | 69 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 21, 2021 | clinicaltrials |
| NCT03329846 | An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | completed | Phase 3 | 20 | Bristol-Myers SquibbINDUSTRY | 16 | Jul 9, 2021 | clinicaltrials |
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer(ExteNET) | completed | Phase 3 | 2,840 | Puma Biotechnology, Inc.INDUSTRY | 40 | Jun 11, 2021 | clinicaltrials |
| NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting(NALA) | completed | Phase 3 | 621 | Puma Biotechnology, Inc.INDUSTRY | 28 | Jun 11, 2021 | clinicaltrials |
| NCT03280264 | Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism | completed | Phase 3 | 18 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT03536182 | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer(CIPHER) | withdrawn | Phase 3 | 0 | University of Texas Southwestern Medical CenterOTHER | 2 | May 26, 2021 | clinicaltrials |
| NCT01419665 | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)(ASSIST_FL) | completed | Phase 3 | 629 | SandozINDUSTRY | 26 | May 14, 2021 | clinicaltrials |
| NCT01763164 | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | completed | Phase 3 | 402 | PfizerINDUSTRY | 27 | Mar 22, 2021 | clinicaltrials |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | terminated | Phase 3 | 1,351 | GlaxoSmithKlineINDUSTRY | 32 | Mar 5, 2021 | clinicaltrials |
| NCT00866697 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 940 | Novartis PharmaceuticalsINDUSTRY | 17 | Feb 16, 2021 | clinicaltrials |
| NCT02369874 | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer(EAGLE) | completed | Phase 3 | 736 | AstraZenecaINDUSTRY | 24 | Feb 10, 2021 | clinicaltrials |
| NCT01271712 | Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)(GRID) | completed | Phase 3 | 199 | BayerINDUSTRY | 17 | Jan 29, 2021 | clinicaltrials |
| NCT01774786 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer(JACOB) | completed | Phase 3 | 780 | Hoffmann-La RocheINDUSTRY | 32 | Dec 30, 2020 | clinicaltrials |
| NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer(ATRACT-1) | terminated | Phase 3 | 1,285 | Novartis PharmaceuticalsINDUSTRY | 26 | Dec 24, 2020 | clinicaltrials |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials